Treatment of Neurasthenia (weakness in nerves) with Unani medicine Majoon-e-Lana

Phase 3

Not yet recruiting

• Conditions: Other specified nonpsychotic mental disorders,

• Registration Number: CTRI/2023/09/057339
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a single centric open trial in patients with á¸Œu‘f A‘ṣÄb(Neurasthenia).After screening, patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at every two weeks. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 6 weeks. Laboratory parameters for safety assessment will be conducted at baseline, 2nd week and on completion of the protocol therapy

**Composition of *Majoon-e-Lana***

| | | | | |

| --- | --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / Scientific Name**

**Part Used**

**Quantity**

|1.

*Azaraqi Mudabbar*

*Strychnos nux-vomica* L.

Seed

20g

|2.

*Filfil Safaid*

*Piper nigrum* L.

Fruit

10g

|3.

*Filfil Siyah*

*Piper nigrum* L.

Fruit

10g

|4.

*Darchini*

*Cinnamomum zeylanicum* B.

Inner stem bark

10g

|5.

*Filfil Daraz*

*Piper longum* L.

Fruit

10g

|6.

*Jauzbuwa*

*Myristica fragrans* H.

Endosperm

10g

|7.

*Bisbasa*

*Myristica fragrans* H.

Arillus

10g

|8.

*Mastagi*

*Pistacia lentisus* L.

Resin

10g

|9.

*Sad Kufi*

*Cyperus rotundus* L.

Rhizome

10g

|10.

*Zanjabeel*

*Zingiber officinale* R.

Rhizome

10g

|11.

*Qaranful*

*Syzygium aromaticum* M.

Flower bud

10g

|12.

*Aamla*

*Emblica officinalis* G.

Fruit

10g

|13.

*Sumbul-ut-Teeb*

*Nardostachys jatamansi* D.

Rhizome

10g

|14.

*Heel Khurd*

*Elettaria cardamomum* M.

Fruit

10g

|15.

*Nankhwah*

*Trachyspermum ammi*L.

Fruit

10g

|16.

*Badiyan*

*Foeniculum vulgare* M.

Fruit

10g

|17.

*Zafran*

*Crocus sativus* L.

Stamen & Stigma

10g

|18.

*Sandal Safaid*

*Santalum album* L.

Heart wood

10g

|19.

*Ood-e-Balsan*

*Balsamodendronopobalsamum K.*

Wood

10g

|20.

*Agar*

*Aquilariaagallocha*

Heart wood

10g

|21.

*Asal /Qand Safaid*

*Honey/Sugar*

----

600g

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-22
• Last Update Posted: 2023-11-09

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients of either gender in the age group of 18-60 years 2.
• Patients having Ḍu‘f A‘ṣÄb(Neurasthenia) as per the diagnostic criteria.

Exclusion Criteria

• Patients below the age of 18 and above the age of 60 years 2.
• Patients having any systemic disease, chronic debilitating disease, T.B., Diabetes Mellitus etc.
• History of any kind of addiction (Alcohol, Drugs and etc.) 4.
• Known case of Carpal tunnel syndrome, herniated disc syndrome, peripheral nerve injury.
• Known cases of Any Neuromuscular abnormalities,neuromuscular junction disorders, Myasthenia gravis, Muscular disorders, Diabetic neuropathy, Autonomic neuropathies 6.
• Pregnancy and lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of trial drug will be assessed on the basis of Clinical Global Impression (CGI) improvement of severity scale and the Visual Analogues Scales for the sense of fatigue and well-being.	At every 2 weeks for 6 weeks

Secondary Outcome Measures

Name	Time	Method
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.	At baseline, 2nd week & at 6th week.

Trial Locations

Locations (1)

Regional Research Institute of Unani Medicine (RRIUM), New Delhi; 🇮🇳 Delhi, DELHI, India

Regional Research Institute of Unani Medicine (RRIUM), New Delhi

🇮🇳Delhi, DELHI, India

Dr Lubna Fatima

Principal investigator

7827433455

drfatima35@gmail.com